UK markets open in 2 hours 8 minutes

Gerresheimer AG (GRRMF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
91.850.00 (0.00%)
At close: 10:36AM EST
Full screen
Trade prices are not sourced from all markets
Previous close91.85
Open91.85
BidN/A x N/A
AskN/A x N/A
Day's range91.85 - 91.85
52-week range91.85 - 111.13
Volume100
Avg. volume4
Market cap2.884B
Beta (5Y monthly)0.96
PE ratio (TTM)29.37
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield1.51 (1.65%)
Ex-dividend date10 Jun 2021
1y target estN/A
All
News
  • EQS Group

    Gerresheimer AG: Gerresheimer on growth course

    DGAP-News: Gerresheimer AG / Key word(s): Quarter Results/9 Month figures12.10.2021 / 07:00 The issuer is solely responsible for the content of this announcement. Core business revenue shows third-quarter organic growth of 9.8 % Strategic positioning as innovative provider of biotech, pharma and beauty solutions delivers results Adjusted EBITDA margin in core business organically at 20.9 % in third quarter Third-quarter adjusted earnings per share rise organically by 5.2 % Guidance confirmed for

  • EQS Group

    Gerresheimer AG: Continuity on the Management Board: Gerresheimer extends contract with CFO Dr. Bernd Metzner ahead of schedule by a further five years

    DGAP-News: Gerresheimer AG / Key word(s): Personnel/Contract09.09.2021 / 09:00 The issuer is solely responsible for the content of this announcement.Continuity on the Management Board: Gerresheimer extends contract with CFO Dr. Bernd Metzner ahead of schedule by a further five years Duesseldorf, September 9, 2021 - At its most recent meeting, the Supervisory Board of Gerresheimer AG prematurely extended the contract of Chief Financial Officer Dr. Bernd Metzner (50) by a further five years until

  • EQS Group

    Gerresheimer AG: Gerresheimer accelerates revenue growth

    DGAP-News: Gerresheimer AG / Key word(s): Quarterly / Interim Statement/Half Year Report13.07.2021 / 07:00 The issuer is solely responsible for the content of this announcement.Gerresheimer accelerates revenue growth Organic Group revenue growth of 7.5 %, and 7.1 % in core business Solutions for biotech drugs and high-value solutions continue to drive revenues increase Organic adjusted EBITDA margin at 22.8 % in core business Adjusted earnings per share up organically by 19.1 % to EUR 1.28 Guida